港股异动|荣威国际涨近4%收入创半年度新高中期纯利升23.7%
格隆汇8月20日丨荣威国际(03358.HK)涨近4%,报3.7港元,成交266万港元,总市值39亿港元。荣威国际(03358.HK)公布,截至2019年6月30日止6个月,公司实现客户合约收益6.02亿美元,同比增长14.6%,创半年度历史新高;毛利1.55亿美元,同比增长23.8%;EBITDA 7479.66万美元,同比增长29.0%;纯利4547.93万美元,同比增长23.7%,基本每股盈利0.0418美元。公告称,收入与利润的增长主要由于全球研究及开发团队的产品开发创新,以及不断地进行现有产品更新及新产品的推广。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.